X-ZELL appoints Sebastian Grote as Managing Director
Sebastian Grote as Managing Director, effective from 1 March 2022.Singapore, March 2022 – Singaporean medical technology specialist X-ZELL has appointed
Grote previously served as Head of Marketing & Strategy at X-ZELL and has been with the company since 2017, when it first came out of stealth mode to raise a two-part, USD 5.6m seed round.
Since then, he initiated a series of global brand-building campaigns that saw X-ZELL evolve from a Bangkok-based research company into one of the highest-ranked medical technology start-ups in the world with offices in Thailand, Singapore, Germany and the US.
Grote also co-authored X-ZELL’s breakthrough study on the accuracy of tumour-associated circulating endothelial cells as a screening biomarker for clinically significant prostate cancer, which was published in Cancers in late 2019.
During his time helming the Marketing & Strategy department, X-ZELL won the coveted MedTech Innovator APAC competition as well as the Startup SG Award, and was ranked as the second most innovative health technology start-up in the world by Galen Growth.
Grote will be sharing more on his journey at the 2022 Intrigue MAdTech Summit in Singapore, joining an illustrious line-up including Google’s Guneet Singh, IBM’s Arun Cavale, Candina Weston of Microsoft, Geoff Tan of OIO Singapore and more.
More information and pre-registration here: https://zcu.io/zm5e
Managing Director X-ZELL Biotech Pte. Ltd.
X-ZELL is an award-winning medical technology company specialising in the detection and digitization of atypical cells from body liquids such as blood and pleural fluid. Atypical cells are the universal language of cancer diagnostics and commonly found in tissue or fluid samples that were surgically collected from the suspected site. By enabling cytology centres worldwide to detect atypical cells in non-invasive sample material and process them digitally at a new level of detail, we make highly accurate, non-invasive diagnostics accessible at scale.